このエントリーをはてなブックマークに追加


ID 71391
フルテキストURL
fulltext.pdf 1.17 MB
著者
Tanaka, Takaaki Department of Hematology, Oncology and Respiratory Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Makimoto, Go Department of Respiratory Medicine, Okayama University Hospital
Nakamura, Naoki Department of Hematology, Oncology and Respiratory Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Kato, Yuka Department of Thoracic Oncology and Medicine, National Hospital Organization Shikoku Cancer Center Kaken ID
Oze, Isao Division of Cancer Information and Control, Aichi Cancer Center Research Institute
Yokoyama, Toshihide Department of Respiratory Medicine, Kurashiki Central Hospital
Kuyama, Shoichi Department of Respiratory Medicine, Iwakuni Clinical Center
Senoo, Satoru Department of Respiratory Medicine, NHO Fukuyama Medical Center
Inoue, Koji Department of Respiratory Medicine, Ehime Prefectural Central Hospital
Ichikawa, Hirohisa Department of Respiratory Medicine, KKR Takamatsu Hospital
Maeda, Yoshinobu Department of Respiratory Medicine, Okayama University Hospital Kaken ID researchmap
Togashi, Yosuke Department of Respiratory Medicine, Okayama University Hospital ORCID Kaken ID researchmap
Hotta, Katsuyuki Center for Innovative Clinical Medicine, Okayama University Hospital Kaken ID publons researchmap
抄録
Background
Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting toxicity of paclitaxel (PTX)-containing regimens, and no preventive strategy has been established. We evaluated goshajinkigan (GJG), a traditional Japanese herbal medicine (Kampo), for preventing CIPN during PTX-containing chemotherapy.
Materials and Methods
In this open-label, randomized phase II trial across 7 institutions in Japan, patients with malignant tumors scheduled for ≥4 courses of carboplatin plus PTX (≥150 mg/m²) were randomized 1:1 to GJG or control, with minimization by cancer type and age. The primary endpoint was grade ≥2 CIPN incidence within 4 courses. The protocol-prespecified primary analysis used an unstratified 2-sided log-rank test (α = 0.10); a supportive stratified analysis accounted for the minimization factors.
Results
Sixty-five patients were randomized (GJG, 32; control, 33); 52 (80.0%) had lung cancer. Grade ≥2 CIPN occurred in 28.1% (9/32) of the GJG arm vs 51.5% (17/33) of the control arm; the protocol-prespecified unstratified log-rank P value was .013, with a corresponding HR of 0.34 (90% CI, 0.16-0.72). In the stratified analysis accounting for cancer type and age, the estimate remained in favor of GJG but was attenuated and less precise (HR, 0.48; 90% CI, 0.22-1.02; stratified log-rank P = .101). Grade 3-5 adverse-event incidence was similar between arms.
Conclusion
GJG was associated with fewer grade ≥2 CIPN events in this predominantly lung-cancer population. Given the open-label design and uncertainty in the stratified analysis, these findings represent a phase II preventive signal warranting confirmation in a double-blind, placebo-controlled phase III trial.
キーワード
chemotherapy-induced peripheral neuropathy
paclitaxel
goshajinkigan
Kampo
randomized controlled trial
発行日
2026-09-09
出版物タイトル
The Oncologist
巻
31巻
号
10号
出版者
Oxford University Press (OUP)
開始ページ
oyag352
ISSN
1083-7159
NCID
AA11157189
資料タイプ
学術雑誌論文
言語
英語
OAI-PMH Set
岡山大学
著作権者
© The Author(s) 2026.
論文のバージョン
publisher
PubMed ID
DOI
関連URL
isVersionOf https://doi.org/10.1093/oncolo/oyag352
ライセンス
https://creativecommons.org/licenses/by/4.0/
Citation
Takaaki Tanaka, Go Makimoto, Naoki Nakamura, Yuka Kato, Isao Oze, Toshihide Yokoyama, Shoichi Kuyama, Satoru Senoo, Koji Inoue, Hirohisa Ichikawa, Yoshinobu Maeda, Yosuke Togashi, Katsuyuki Hotta, Preventive effect of goshajinkigan on paclitaxel-induced peripheral neuropathy: an open-label, randomized phase II study (OLCSG2101), The Oncologist, Volume 31, Issue 10, October 2026, oyag352, https://doi.org/10.1093/oncolo/oyag352
助成情報
( 岡山大学病院 / Okayama University Hospital )
( Chugoku Occupational Health Association )